You just read:

Early Launch Metrics for Janssen's Tremfya May Lag Those of Lilly's Taltz at a Similar Post-Launch Period, but Signs Indicate the New IL-23 Inhibitor is Poised to Set a New Bar for Efficacy in Skin

News provided by

Spherix Global Insights

Sep 14, 2017, 04:00 ET